Astec Lifesciences Ltd
Agro Chemicals | Small Cap
Astec Lifesciences, operating in the Chemical & Petrochemicals sector, shows a mixed financial performance. The company demonstrates strengths in solvency, driven by a manageable debt-to-equity ratio and reasonable interest coverage. However, it faces challenges in efficiency, particularly in inventory and receivables management. Growth metrics reveal a decline in revenue and operating profit, alongside a concerning trend in earnings per share. While asset growth remains strong, profitability is under pressure due to shrinking margins and returns. The financial ratios show strengths in book value per share and capital expenditure management, but weaknesses in adjusted earnings and dividend payouts. Overall, Astec Lifesciences exhibits financial resilience but needs to address declining profitability and efficiency to ensure sustainable growth.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio2.80
- Financial Ratio5.60
- Profitability Ratio2.30
- Efficiency Ratio2.00
- Coverage Ratio6.00
- Solvency Ratio9.09
- Liquidity Ratio0.00
- Peer Assessment
- Management AssessmentWeak
- Risk AssessmentWeak
- 1 HourBearish
- 2 HoursBearish
- 4 HoursNeutral
- 1 DayNeutral
- 1 WeekNeutral
- 1 MonthBullish
Astec Lifesciences, operating in the Chemical & Petrochemicals sector, shows a mixed financial performance. The company demonstrates strengths in solvency, driven by a manageable debt-to-equity ratio and reasonable interest coverage. However, it faces challenges in efficiency, particularly in inventory and receivables management. Growth metrics reveal a decline in revenue and operating profit, alongside a concerning trend in earnings per share. While asset growth remains strong, profitability is under pressure due to shrinking margins and returns. The financial ratios show strengths in book value per share and capital expenditure management, but weaknesses in adjusted earnings and dividend payouts. Overall, Astec Lifesciences exhibits financial resilience but needs to address declining profitability and efficiency to ensure sustainable growth.
Latest Report
View AllLatest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
Overall Valuation Score
P/E RATIO (TTM)
-1.36
Industry Median
26.62
Small Cap Median
24.65
P/E RATIO
-1.15
P/B RATIO
0.37
Industry Median
3.32
Small Cap Median
3.13
P/S RATIO
N/A
Industry Median
1.80
Small Cap Median
1.46
Others
PEG RATIO
0.00
EV/EBITDA RATIO
-2.57
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹69.06 as on Feb 20, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
Quarterly Report⬤27th Apr 26
Audited Standalone Financial Results for the Quarter and Full Year Ending March 31, 2026
UNDEFINED SENTIMENT
The growth ratios present a mixed picture. While asset growth is strong, declines in revenue, operating profit, and earnings per share raise concerns about the company's ability to sustain growth. The company needs to address the factors contributing to these declines to ensure future growth prospects. Diversifying revenue streams and exploring new market opportunities could help revitalize growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 21.98 | -7.24 | -27.07 | -16.81 | 17.59 |
| Operating Profit Growth Rate | 37.5 | -50 | -107.79 | 1000 | -92.42 |
| Earnings Per Share (EPS) Growth | 38.15 | -71.56 | -283.61 | 187.16 | -39.63 |
| Asset Growth Rate | 32.3 | 9.14 | -0.41 | -9.64 | 6.92 |
| Net Income Growth Rate | 38.46 | -71.11 | -280.77 | 187.23 | -40 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The financial ratios present a mixed view. Strong book value per share and effective capital expenditure management are positive signs. However, low adjusted earnings per share and dividend payouts are areas of concern. Enhancing profitability and shareholder returns would improve overall financial health. Improving earnings quality and optimizing capital allocation can enhance shareholder value.
| Financial Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | 45 | 13 | -23.5 | -68.5 | -35.91 |
| Cash Earnings Per Share (Cash EPS) | 62 | 30 | -5.5 | -45.5 | -16.36 |
| Book Value Per Share | 198.5 | 210 | 185 | 117.5 | 177.27 |
| Dividend Per Share (DPS) | 1.2 | 1.37 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 103.9 | 116.5 | 135.1 | 15.9 | 4.8 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The profitability ratios point to significant challenges. Declining gross profit, returns on capital, equity, and assets, along with shrinking operating and net margins, indicate a squeeze on profitability. Addressing these issues is crucial for improving financial performance. Focusing on cost control, revenue enhancement, and efficient asset utilization can help boost profitability.
| Profitability Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Profit Margin | 17.73 | 6.85 | -9.17 | -28.87 | -11.16 |
| Return on Capital Employed (ROCE) | 22 | 8 | -4 | -13 | -5 |
| Return on Equity (ROE) | 22.67 | 6.19 | -12.7 | -57.45 | -20.77 |
| Return on Assets (ROA) | 17.17 | 7.87 | -0.62 | -7.49 | -0.53 |
| Operating Margin | 22.75 | 12.26 | -1.31 | -17.32 | -1.12 |
| Net Margin | 13.29 | 4.14 | -10.26 | -35.43 | -18.08 |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The efficiency ratios indicate challenges in operational management. Low turnover ratios for inventory and receivables suggest that the company may be struggling to efficiently manage its working capital. High receivable days indicate that it takes a long time to collect payments, which can tie up cash. Addressing these inefficiencies is crucial for improving cash flow and overall operational performance.
| Efficiency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | 1.99 | 1.97 | 1.19 | 0.76 | 0.94 |
| Inventory Turnover Ratio | 3.8 | 2.43 | 2.04 | 2.76 | 3.34 |
| Receivables Turnover Ratio | 2.94 | 2.93 | 2.83 | 2.41 | 2.27 |
| Days Sales in Inventory Ratio | 96.05 | 150.21 | 178.92 | 132.25 | 109.28 |
| Receivable Days | 124.15 | 124.57 | 128.98 | 151.45 | 160.79 |
| Capital Turnover Ratio | 1.71 | 1.46 | 0.8 | 0.74 | 1.02 |
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
The coverage ratios suggest limited ability to meet financial obligations. Further examination is needed to determine the company's capacity to cover interest and dividend payments. Strengthening the ability to meet financial obligations is crucial for maintaining financial stability and investor confidence. Improving earnings and cash flow management can enhance these coverage ratios.
| Coverage Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Interest Coverage Ratio | 14.44 | 2.67 | -1.48 | -2.81 | -1.31 |
| Equity Dividend Coverage Ratio | 33.33 | 8.33 |
Interest Coverage Ratio
Equity Dividend Coverage Ratio
The company's solvency position reflects a balanced financial structure. A low debt-to-equity ratio suggests the company relies more on equity than debt for financing, reducing financial risk. A good interest coverage ratio indicates the company can comfortably meet its interest obligations from its earnings. This suggests financial stability and a capacity to handle its debt obligations effectively, contributing to long-term sustainability.
| Solvency Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debt Ratio | 0 | 0.03 | 0.35 | 0.54 | 0.11 |
| Debt to Equity Ratio | 0 | 0.03 | 0.54 | 1.17 | 0.12 |
| Equity Ratio | 1 | 0.97 | 0.65 | 0.46 | 0.89 |
| Debt To Asset Ratio | 0 | 0.01 | 0.2 | 0.32 | 0.05 |
Debt Ratio
Debt to Equity Ratio
Interest Coverage Ratio
The company's liquidity position cannot be reliably assessed due to incomplete data. A comprehensive liquidity analysis requires a detailed review of current assets and liabilities, as well as cash flow management practices. Without sufficient information, it is not possible to determine the company's ability to meet its short-term obligations. Further investigation and data are needed to provide a meaningful assessment of Astec Lifesciences' liquidity.
| Liquidity Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Current Ratio | 1.07 | 0.97 | 1.04 | 0.98 | 0.92 |
| Quick Ratio | 0.69 | 0.44 | 0.56 | 0.55 | 0.65 |
| Cash Ratio | 0 | 0 | 0 | 0.01 | 0.02 |
| Operating Cash Flow Ratio | 0.05 | 0.14 | 0.02 | -0.02 | -0.16 |
Current Ratio
Quick Ratio
Cash Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Astec Lifesciences Ltd | 4.06 | -1.15 | Neutral | -5.00 | -36.36 | -81.00 |
The management effectiveness of Astec Lifesciences Ltd is weak. While promoter holding is strong, the company has exhibited declining financial performance, particularly in sales and profit growth. The negative operating profit margins and net losses in recent quarters raise concerns about operational efficiency and profitability. Increased borrowings and a high cash conversion cycle further contribute to a negative outlook on management's strategic and operational capabilities.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Promoter Holding | 66.74% | Strong confidence and alignment with shareholders. |
| CONS | Sales Growth (3Y) | -6% | Declining revenue expansion. |
| Operating Profit Margin (TTM) | -19% | Deteriorating operational efficiency. | |
| Net Profit (TTM) | -104 | Negative profitability. | |
| ROCE (LY) | -4% | Poor capital utilization. | |
| Debt/Equity Ratio (Sept 2024) | 0.97 | High leverage. | |
| Cash Conversion Cycle (Mar 2024) | 256 days | Inefficient working capital management. |
Financial Performance & Growth
Astec Lifesciences exhibits a concerning trend in financial performance. The compounded sales growth has declined over the years, with a negative 6% over the last 3 years and further down to -25% TTM. Quarterly results show fluctuating sales and a significant drop in operating profit margin (OPM) to -67% in June 2024 and -20% in September 2024. Net profit has also been negative in recent quarters. The YOY profit growth % is also declining, indicating increasing losses.
| Metric | 2013-2015 | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Sales Growth % (Avg) | 20.74% | 12.86% | 11.49% | 21.93% | -7.15% | -27.06% |
| OPM % (Avg) | 17.67% | 18% | 19.33% | 23% | 12% | -1% |
Capital Efficiency & Returns
The capital efficiency and returns for Astec Lifesciences are weak. The Return on Capital Employed (ROCE) has declined significantly, with a last year value of -4%. This indicates that the company is not effectively utilizing its capital to generate profits. Return on Equity (ROE) is also negative at -12% for the last year, suggesting poor returns on shareholder funds. The Cash Conversion Cycle is high at 256 days as of March 2024, indicating inefficient working capital management.
| Metric | 2013-2015 | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| ROCE % (Avg) | 13.33% | 18% | 21.33% | 22% | 8% | -4% |
Financial Health & Prudence
Astec Lifesciences shows signs of poor financial health. The borrowings have increased significantly over the years, reaching ₹ 500 Cr. by September 2024. The Debt/Equity ratio is 0.97 as of September 2024, indicating high leverage.
| Metric | 2013-2015 | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 (Sept) |
|---|---|---|---|---|---|---|
| Borrowings (Avg) | 83 Cr | 126.33 Cr | 154 Cr | 279 Cr | 341 Cr | 500 Cr |
| Debt/Equity Ratio | 0.77 | 0.91 | 0.77 | 0.74 | 0.84 | 0.97 |
Strategic & Operational Indicators
The operational efficiency of Astec Lifesciences is weak. The Cash Conversion Cycle is high, reaching 256 days in March 2024, indicating inefficiencies in managing working capital. Debtor days and Inventory days are also relatively high, suggesting challenges in collecting receivables and managing inventory effectively.
| Metric | 2013-2015 | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Debtor Days (Avg) | 122.67 | 127.67 | 112.67 | 148 | 90 | 135 |
| Inventory Days (Avg) | 158 | 144 | 119 | 176 | 268 | 224 |
| Cash Conversion Cycle (Avg) | 130.67 | 125 | 55.67 | 145 | 197 | 256 |
The risk assessment for Astec Lifesciences is rated as Red due to the significant decline in profitability, indicated by negative profit margins and net losses, raises concerns about the company's financial stability. The increased borrowings and high debt-to-equity ratio further amplify the financial risk. Inefficient working capital management, reflected in the high cash conversion cycle, adds to the operational challenges.
Segment performance volatility
The quarterly results show significant volatility in segment performance. Fluctuations in sales and profit figures from quarter to quarter indicate instability and unpredictability in the company's revenue streams.
| Quarter | Sales Growth % | Net Profit | YOY Profit Growth % |
|---|---|---|---|
| Sep 2023 | -44.54% | -13 | -173% |
| Dec 2023 | -56.66% | -24 | -2,995% |
| Mar 2024 | 21.09% | -1 | 81% |
| Jun 2024 | -51.44% | -40 | -385% |
| Sep 2024 | -11.05% | -39 | -187% |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1067.01Bearish
- SMA 2066.87Bearish
- SMA 5066.58Bullish
- EMA 1066.96Bearish
- EMA 2066.91Bearish
- EMA 5066.79Bearish
- DEMA 1066.99Bearish
- DEMA 2067.04Bearish
- DEMA 5066.80Bearish
- TEMA 1066.94Bearish
- TEMA 2067.01Bearish
- TEMA 5066.98Bearish
- MACD0.09Bearish
- ADX16.90Weak Trend
- IndicatorValueSignal
- RSI47.61Neutral
- CCI-39.10Neutral
- ROC 90.32Bullish
- ROC 14-0.09Bearish
- ROC 25-0.63Bearish
- Stoch K32.27Neutral
- Stoch D36.52Neutral
- IndicatorValueSignal
- BB Upper67.61Neutral
- BB Middle66.87Neutral
- BB Lower66.12Neutral
- ATR1.09Low Volatility
- IndicatorValueSignal
- MFI57.67Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1066.75Bearish
- SMA 2066.84Bearish
- SMA 5066.57Bullish
- EMA 1066.77Bearish
- EMA 2066.70Bearish
- EMA 5066.72Bearish
- DEMA 1066.82Bearish
- DEMA 2066.79Bearish
- DEMA 5066.69Bearish
- TEMA 1066.76Bearish
- TEMA 2066.95Bearish
- TEMA 5066.50Bullish
- MACD0.07Bullish
- ADX21.12Weak Trend
- IndicatorValueSignal
- RSI49.04Neutral
- CCI-71.27Neutral
- ROC 9-0.02Bearish
- ROC 14-0.02Bearish
- ROC 252.41Bullish
- Stoch K24.82Neutral
- Stoch D28.49Neutral
- IndicatorValueSignal
- BB Upper67.41Neutral
- BB Middle66.84Neutral
- BB Lower66.26Neutral
- ATR1.33Low Volatility
- IndicatorValueSignal
- MFI46.53Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1066.71Bearish
- SMA 2066.07Bullish
- SMA 5066.42Bullish
- EMA 1066.58Bullish
- EMA 2066.59Bullish
- EMA 5066.42Bullish
- DEMA 1066.67Bearish
- DEMA 2066.51Bullish
- DEMA 5066.97Bearish
- TEMA 1066.81Bearish
- TEMA 2066.45Bullish
- TEMA 50N/AN/A
- MACD-0.04Bullish
- ADX15.75Weak Trend
- IndicatorValueSignal
- RSI49.92Neutral
- CCI53.08Neutral
- ROC 9-0.89Bearish
- ROC 142.65Bullish
- ROC 25-3.55Bearish
- Stoch K58.16Neutral
- Stoch D58.37Neutral
- IndicatorValueSignal
- BB Upper67.68Neutral
- BB Middle66.07Neutral
- BB Lower64.45Neutral
- ATR1.86Low Volatility
- IndicatorValueSignal
- MFI61.11Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1066.21Bullish
- SMA 2067.22Bearish
- SMA 5066.81Bearish
- SMA 10064.96Bullish
- SMA 20067.54Bearish
- EMA 1066.78Bullish
- EMA 2066.67Bullish
- EMA 5066.12Bullish
- EMA 10066.20Bullish
- EMA 20068.67Bearish
- DEMA 1066.82Bearish
- DEMA 2066.99Bearish
- DEMA 5066.74Bullish
- DEMA 10064.81Bullish
- DEMA 20063.10Bullish
- TEMA 1066.79Bullish
- TEMA 2066.85Bearish
- TEMA 5067.47Bearish
- TEMA 10066.73Bullish
- TEMA 20062.12Bullish
- MACD0.22Bearish
- ADX15.87Weak Trend
- IndicatorValueSignal
- RSI51.01Neutral
- CCI-8.61Neutral
- ROC 14-4.46Bearish
- ROC 256.79Bullish
- Stoch K31.04Neutral
- Stoch D29.12Neutral
- IndicatorValueSignal
- BB Upper71.97Neutral
- BB Middle67.22Neutral
- BB Lower62.46Neutral
- ATR2.97Low Volatility
- IndicatorValueSignal
- MFI23.85Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 2065.04Bullish
- SMA 5069.23Bearish
- EMA 2066.30Bullish
- EMA 5069.68Bearish
- DEMA 2065.43Bullish
- DEMA 5064.03Bullish
- TEMA 2067.32Bearish
- TEMA 5060.99Bullish
- MACD-0.40Bullish
- ADX14.22Weak Trend
- IndicatorValueSignal
- RSI48.58Neutral
- CCI-52.50Neutral
- ROC 147.18Bullish
- ROC 25-1.14Bearish
- Stoch K72.78Neutral
- Stoch D69.98Neutral
- IndicatorValueSignal
- BB Upper74.15Neutral
- BB Middle65.04Neutral
- BB Lower55.93Neutral
- ATR6.72Low Volatility
- IndicatorValueSignal
- MFI30.99Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 664.86Bullish
- SMA 1269.77Bullish
- SMA 2482.81Bearish
- EMA 667.33Bullish
- EMA 1270.02Bullish
- EMA 2471.58Bullish
- DEMA 666.32Bullish
- DEMA 1265.08Bullish
- DEMA 2474.75Bearish
- TEMA 669.00Bullish
- TEMA 1262.29Bullish
- TEMA 2466.61Bullish
- MACD7.78Bearish
- ADX26.29Strong Trend
- IndicatorValueSignal
- RSI53.00Neutral
- CCI22.01Neutral
- ROC 25-20.24Bearish
- ROC 50211.03Bullish
- Stoch K24.81Neutral
- Stoch D45.06Neutral
- IndicatorValueSignal
- BB Upper104.03Neutral
- BB Middle77.51Neutral
- BB Lower50.98Neutral
- ATR15.18Low Volatility
- IndicatorValueSignal
- MFI68.48Neutral